RFL News and Press, Rafael Holdings Inc. Class B From 06/06/19

Newark, NJ, June 06, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, has announced that Sanjeev Luther, President and Chief Executive Officer of Rafael, i...

Rafael Holdings (NYSEMKT: RFL ): Q3 GAAP EPS of -$0.07. Revenue of $1.38M (+26.6% Y/Y) Press Release More news on: Rafael Holdings, Inc., Earnings news and commentary, Healthcare stocks news, ,

NEWARK, N.J. , June 5, 2019 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE American: RFL), reported revenue of $1.4 million and a loss per share of $0.07 for the third quarter of its 2019 fiscal year, the three months ended April 30 , 2019.  3Q19 Highlights ...

Newark, NJ, June 04, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, will present at the Jefferies 2019 Healthcare Conference on Friday, June 7 at 11:30 a.m....

Newark, NJ, May 16, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that Sanjeev Luther, President and Chief Executive Officer, was named ...

Newark, NJ, May 13, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced the appointment of Mona M. Wahba, MD, MSM, as Senior Vice President f...

This article is part of a series that provides an ongoing analysis of the changes made to Kahn Brothers' 13F stock portfolio on a quarterly basis. It is based on Kahn Brothers' regulatory 13F Form filed on 05/06/2019. Please visit our Tracking Kahn Brothers Portfolio series to get an idea ...

Givat Ram High-Tech Village, Jerusalem, March 29, 2019 (GLOBE NEWSWIRE) -- Lipomedix, a clinical-stage, oncology-focused pharmaceutical company, involved in the development of innovative, safe and effective cancer therapy based on a pegylated liposomal drug delivery platform, today announce...

Rafael Pharmaceuticals, a subsidiary Rafael Holdings (NYSEAMERICAN: RFL ) is reshaping drug options for hard-to-treat forms of cancer, such as acute myeloid leukemia (AML) and metastatic pancreatic cancer. Its lead drug candidate, called devimistat (CPI-613), works to target enzymes involved...

Rafael Holdings (NYSEMKT: RFL ): Q2 GAAP EPS of -$0.08. More news on: Rafael Holdings, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...